Finn
GRFS Biopharma · Plasma medicines · Turnaround · Leveraged · Thesis updated November 8, 2026

Leverage falls under target but China albumin pressure deepens

01 Running thesis

A cleaner operational turnaround held back by the balance sheet

The bull case is that Grifols is finally doing the hard work its balance sheet demanded. It refinanced 2027 maturities, pushed major debt risk out, and keeps improving plasma operations. The Egypt platform is expected to collect about 1 million liters in 2026 and scale to about 3 million liters by 2029. That matters because cheaper plasma can lift margins.

The business demand picture is also solid. Immunoglobulin, the core medicine group, has regained lost U.S. share after the pandemic disruption. Management expects that franchise to grow around a 6% to 8% CAGR, meaning a steady yearly growth rate over time. Recent launches like Fesilty in the U.S. show pipeline progress.

The bear case has not gone away. Grifols still carries a heavy debt load, even though total net leverage dropped to 3.98x in the third quarter. Albumin in China continues to contract, falling 13.2% in the third quarter of 2026 due to high channel inventories. Management also delayed the expected update on the possible U.S. Biopharma IPO to 2027, which leaves a key debt reduction catalyst unclear.

Finn's view fits that mix. Growth is real, valuation is not stretched, but performance and financial health still reflect a company working through past leverage and execution problems.

Nov 2026→Q3 2026 results showed total net leverage falling below 4.0x, but China albumin sales dropped 13.2% and the U.S. Biopharma IPO update was pushed to 2027.
Jul 2026→Q2 2026 earnings showed steady execution with the U.S. launch of Fibrinogen and the new Evansys Diagnostics platform. The U.S. Biopharma IPO remains a key overhang with no new details provided.
May 2026▲Q1 2026 strengthened the turnaround case. Grifols confirmed Egypt plasma is on track for about 1 million liters this year, closed 29 weak U.S. donor centers, and refinanced all 2027 maturities, but gave no detail on the U.S. Biopharma IPO.
Apr 2026▲The 2025 Form 20-F added a major catalyst: a possible IPO of a minority stake in U.S. Biopharma to support debt reduction and growth investment. It also showed new credit facilities of $2 billion and EUR 1.25 billion maturing in April 2033.
Nov 2025→Q3 2025 showed stronger cash flow guidance and a normalized 6% to 8% IG growth target. The offset was weaker albumin in China and a delayed U.S. path for acquired fibrinogen deficiency.
Jul 2025▲Q2 2025 showed leverage down to 4.2x under the credit agreement and the dividend was reinstated at EUR 0.15. New pressure came from U.S. dollar weakness and China healthcare cost controls.
May 2025▲Q1 2025 showed subcutaneous IG momentum and more than EUR 200 million year-over-year improvement in free cash flow. Leverage moved under 4.5x, while China albumin shipment issues were tied to a completed license renewal.
Apr 2025▲The 2024 Form 20-F confirmed the $1.8 billion Shanghai RAAS stake sale and full ownership of 28 ImmunoTek plasma centers. Both supported debt reduction and tighter control of plasma supply.
02 Business model

Plasma in, proteins out

Grifols runs a vertically integrated plasma model. It collects plasma from donors, processes it in factories, and separates it into proteins used as medicines. That separation process is called fractionation.

The key profit lever is cost per liter, or how much it costs to collect each liter of plasma before it becomes medicine. Grifols is moving toward a two-system model. U.S. plasma mainly serves the U.S. market, while Egypt and other non-U.S. sources serve rest-of-world demand. The goal is to stop shipping as much high-cost U.S. plasma into lower-price markets.

Scale helps, but it also raises execution risk. The company had more than 400 plasma collection centers at the end of 2025, then said in early 2026 it had closed 29 underperforming U.S. donor centers with some volume moved to better sites. If collections, yields, or donor economics slip, the margin story weakens fast.

Cash also depends on timing. Plasma collected today can take time to become finished product. That means growth can use cash before it shows up as revenue.

03 Product portfolio

The medicines that drive the model

Growth engine

Immunoglobulins

This is the core franchise, led by Gamunex, Xembify, and Biotest Yimmugo in the U.S. Demand is strong, and management expects the franchise to normalize around a 6% to 8% CAGR.

Growth engine

Subcutaneous IG

Subcutaneous IG is taken under the skin instead of through an IV. Xembify has been a major growth driver because it can be easier for some patients to use at home.

Cash cow

Albumin

Albumin is a large plasma protein business, but China is pressuring prices and channel inventories remain high. That makes it a cash generator with a current headwind.

Steady

Alpha-1 therapies

Alpha-1 treatments serve patients with a rare protein deficiency that can damage lungs and liver. The SPARTA readout in late 2026 is a watch item for this franchise.

Option

Fibrinogen

Grifols launched its Fesilty fibrinogen product for congenital indications in the U.S. in mid-2026. The company is seeking FDA agreement on trial design for acquired indications.

Steady

Diagnostics

Diagnostics gives Grifols a smaller, steadier business in blood typing and donor screening. The company recently launched the Evansys platform to capture share.

04 Business segments

Biopharma carries the company

Biopharma86%growing fast
Diagnostic8%modest
Bio Supplies2%declining
Others3%modest

The mix uses 2025 net revenue from the 2025 Form 20-F. Biopharma is 86.2% of revenue, so changes in immunoglobulin, albumin, and plasma costs matter far more than the smaller units.

05 Risk factors

What could still break

Debt stays too high

High impact · Medium odds

The 2026 refinancing removed the near 2027 wall and extended major facilities to the next decade. Total net leverage fell to 3.98x in the third quarter of 2026, but Grifols is not a low-debt company. If EBITDA stalls, leverage can stay too high and keep pressure on the stock.

We watchWatch the leverage ratio, free cash flow, and any update on maturities around Q4 2028.

U.S. Biopharma IPO disappoints

High impact · Medium odds

The possible IPO of a minority stake in U.S. Biopharma could help debt reduction. The problem is that management pushed the update to 2027 and has not given key details on valuation, timing, governance, or how proceeds would be used. A weak structure could confuse investors instead of helping them.

We watchWatch for the IPO update in 2027, proposed valuation, percent sold, and stated use of proceeds.

China albumin pricing pressure lasts

Medium impact · High odds

Albumin sales are under pressure in China because of government cost controls and high channel inventories. The segment contracted 13.2% in the third quarter of 2026. A longer price reset would hurt revenue mix and margins.

We watchWatch albumin constant-currency growth and management comments on China hospital pricing and channel inventory.

Egypt scale-up misses

Medium impact · Medium odds

The Egypt plasma platform is central to lowering cost per liter outside the U.S. Grifols targets about 1 million liters in 2026 and about 3 million liters by 2029. Any collection, quality, or logistics issue would slow the margin plan.

We watchWatch annual liters collected in Egypt and cost-per-liter commentary.

New CIDP drugs take share

Medium impact · Medium odds

Some patients with CIDP use immunoglobulin therapy, which is important to Grifols. Novel FcRn inhibitors could compete for those patients. Management has pushed back by saying some patients are switching back to IG, but the threat is real.

We watchWatch CIDP prescription trends, IG volume growth, and FcRn launch data.

Currency and U.S. policy drag EBITDA

Medium impact · Medium odds

A weaker U.S. dollar hurts Grifols when dollar profits are translated into euros. Management said each cent of U.S. dollar depreciation versus the euro has about a EUR 7 million full-year EBITDA headwind. U.S. IRA Part D redesign is another pressure point.

We watchWatch EUR/USD rates, EBITDA guidance, and IRA impact updates.
06 Quick answers

In one breath

What does Grifols actually do?

Grifols collects human plasma and turns it into medicines. Its main products treat immune disorders, albumin needs, Alpha-1 deficiency, and blood clotting problems.

Why does plasma cost matter so much?

Plasma is the raw material for Grifols' main medicines. If the company collects each liter at a lower cost and processes it well, margins can rise.

Is Grifols still risky because of debt?

Yes. The 2026 refinancing reduced near-term refinancing risk, and leverage finally fell below 4.0x. However, the company is still leveraged, and investors should watch free cash flow and proceeds from the possible U.S. Biopharma IPO.

What are the next big catalysts?

The biggest watch items are the 2027 update on the U.S. Biopharma IPO, FDA discussions for acquired fibrinogen indication, and the SPARTA Alpha-1 clinical readout expected in late 2026.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Grifols 2025 Form 20-F
  2. Grifols Q3 2026 earnings transcript
  3. Grifols Q2 2026 earnings transcript
  4. Grifols Q1 2026 earnings transcript
08 Explore the industry

Comparable Drug Manufacturers - General companies

Companies near Grifols, S.A. in Finn's Drug Manufacturers - General industry ranking.

Get started with Finn today